Personalis, Inc. (PSNL) stock
PSNLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30345% above fair value
$14.80+0.00 (0.00%)
Close on Nov 17, 2026Market cap $1.58BP/E –Yield –
Personalis total assets
Total assets on the balance sheet at the end of each period.
Personalis's total assets was $312.14M at Jun 30, 2026. For fiscal 2025 it was $334.16M, up 23.6% from the year before. The highest annual figure on record is $396.53M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $334.16M | +23.6% |
| FY2024 | Dec 31, 2024 | $270.27M | +20.1% |
| FY2023 | Dec 31, 2023 | $225.10M | -23.1% |
| FY2022 | Dec 31, 2022 | $292.70M | -26.2% |
| FY2021 | Dec 31, 2021 | $396.53M | +62.0% |
| FY2020 | Dec 31, 2020 | $244.84M | +55.7% |
| FY2019 | Dec 31, 2019 | $157.29M | +277.5% |
| FY2018 | Dec 31, 2018 | $41.67M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $312.14M | +20.7% |
| Q1 FY2026 | Mar 31, 2026 | $325.40M | +19.1% |
| Q4 FY2025 | Dec 31, 2025 | $334.16M | +23.6% |
| Q3 FY2025 | Sep 30, 2025 | $242.84M | +1.2% |
| Q2 FY2025 | Jun 30, 2025 | $258.68M | +39.4% |
| Q1 FY2025 | Mar 31, 2025 | $273.31M | +40.0% |
| Q4 FY2024 | Dec 31, 2024 | $270.27M | +20.1% |
| Q3 FY2024 | Sep 30, 2024 | $239.89M | +5.8% |
| Q2 FY2024 | Jun 30, 2024 | $185.50M | -25.5% |
| Q1 FY2024 | Mar 31, 2024 | $195.28M | -28.3% |
| Q4 FY2023 | Dec 31, 2023 | $225.10M | -23.1% |
| Q3 FY2023 | Sep 30, 2023 | $226.64M | -28.7% |
| Q2 FY2023 | Jun 30, 2023 | $249.04M | -30.4% |
| Q1 FY2023 | Mar 31, 2023 | $272.18M | -28.5% |
| Q4 FY2022 | Dec 31, 2022 | $292.70M | -26.2% |
| Q3 FY2022 | Sep 30, 2022 | $317.86M | -21.8% |
| Q2 FY2022 | Jun 30, 2022 | $357.98M | -6.6% |
| Q1 FY2022 | Mar 31, 2022 | $380.65M | -3.8% |
| Q4 FY2021 | Dec 31, 2021 | $396.53M | +62.0% |
| Q3 FY2021 | Sep 30, 2021 | $406.69M | +63.5% |
| Q2 FY2021 | Jun 30, 2021 | $383.34M | +163.4% |
| Q1 FY2021 | Mar 31, 2021 | $395.51M | +160.4% |
| Q4 FY2020 | Dec 31, 2020 | $244.84M | +55.7% |
| Q3 FY2020 | Sep 30, 2020 | $248.81M | +55.8% |
| Q2 FY2020 | Jun 30, 2020 | $145.52M | -24.1% |
| Q1 FY2020 | Mar 31, 2020 | $151.88M | +264.5% |
| Q4 FY2019 | Dec 31, 2019 | $157.29M | – |
| Q3 FY2019 | Sep 30, 2019 | $159.69M | – |
| Q2 FY2019 | Jun 30, 2019 | $191.85M | – |
| Q4 FY2018 | Dec 31, 2018 | $41.67M | – |
See a number that looks wrong?